In patients with metastatic colorectal cancer (mCRC), improved outcomes have been observed in patients treated with bevacizumab (humanised monoclonal antibody to vascular endothelial growth factor (VEGF)) plus chemotherapy compared with chemotherapy alone ([@bib11]; [@bib20]). Combinations of chemotherapy plus other targeted agents with different mechanisms of action have been explored. However, to date, addition of tyrosine kinase inhibitors (TKIs) of VEGF receptors (VEGFRs) to chemotherapy regimens has failed to improve efficacy in patients with mCRC compared with placebo ([@bib7]; [@bib27]) or bevacizumab ([@bib8]; [@bib23]; [@bib4]) in randomised phase II or phase III trials.

Preclinical studies have shown that agents that bind VEGF may transiently normalise tumour vasculature and increase uptake of cytotoxic drugs ([@bib6]). However, more potent antiangiogenic agents, such as TKIs that target VEGFRs, may actually induce hypoxia and decrease blood flow to the tumour, slowing tumour cell division and impeding delivery of cytotoxic agents, which may antagonise the efficacy of chemotherapeutic agents ([@bib14]). Because of the potential chemotherapy-antagonising effects, intermittent dosing of a potent antiangiogenic agent with a short half-life may be the optimal strategy when administered in combination with chemotherapy.

Axitinib is a potent and selective second-generation inhibitor of VEGFRs 1, 2, and 3 ([@bib10]) that showed single-agent efficacy in phase II studies of various tumour types ([@bib17]; [@bib3]; [@bib16]; [@bib22]; [@bib5]). Axitinib was approved in the United States (Pfizer Inc, 2012), Japan, the European Union, and other countries for the second-line treatment of advanced renal cell carcinoma. A phase I study showed that axitinib may be combined with full-dose 5-fluorouracil (5-FU)/leucovorin/irinotecan (FOLFIRI) or 5-FU/leucovorin/oxaliplatin (FOLFOX) without intolerable toxicities and without affecting the plasma concentration of these drugs in patients with mCRC or other solid tumours ([@bib24]). However, improvements in efficacy have not been evident with continuous axitinib plus chemotherapy compared with bevacizumab plus chemotherapy when used as first- or second-line mCRC treatment ([@bib2]; [@bib12]).

In this study, we explored the safety and efficacy of axitinib dose interruptions before administration of FOLFIRI or FOLFOX in patients with mCRC or other advanced gastrointestinal cancers. Serial fluorine-18 3′-deoxy-3′-fluorothymidine positron emission tomography (^18^FLT-PET) scans ([@bib19]) were performed to explore the effect of 7-day axitinib exposure and subsequent interruption in thymidine uptake and tumour cell proliferation, to aid in determining the optimal administration of axitinib when combined with chemotherapy.

Materials and methods
=====================

Study design
------------

This was a phase I portion of a randomised phase II study evaluating axitinib in combination with chemotherapy and bevacizumab in mCRC ([@bib24]; [@bib12]). The objectives of this portion were to determine the maximum tolerated dose of axitinib administered in an interrupted-dosing schedule, estimate the optimal timing of FOLFIRI or FOLFOX administration following interruption of axitinib dosing based on ^18^FLT-PET scans, determine whether addition of axitinib administered in an interrupted-dosing schedule to FOLFOX or FOLFIRI can reverse pre-existing drug resistance among patients refractory to previous FOLFIRI or FOLFOX regimens, and assess tumour response and safety.

This study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines on Good Clinical Practice, the study protocol and applicable local regulatory requirements and laws. All participants provided written informed consent and agreed to comply with the study protocol. The protocol and informed consent forms were approved by an institutional review board/independent ethics committee. This trial is registered on ClinicalTrials.gov (NCT00460603).

Patients
--------

All eligible adult patients had gastrointestinal cancer, measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST, version 1.0) ([@bib25]), and appropriate lesions for ^18^FLT-PET/computed tomography (CT) analysis (outside a previous radiation field and a diameter \>3 cm for a liver lesion, \>1.5 cm for a pulmonary lesion and \>2 cm for all other lesions). Patients had an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate bone marrow, renal and hepatic function, and baseline blood pressure (BP) \<130/80 mm Hg with antihypertensive medications permitted, and were eligible to receive FOLFIRI or FOLFOX. Key exclusion criteria were major surgery or investigational agent within 4 weeks before enrolment or minor surgery within 2 weeks before enrolment, clinically significant gastrointestinal abnormalities, proteinuria (⩾2+protein by dipstick or ⩾500 mg per 24 h), grade ⩾2 sensory neuropathy, serious or non-healing wound ulcer or bone fracture, current congestive heart failure, or significant bleeding episodes or arterial thrombotic events within 6 months before enrolment.

Study treatments
----------------

During a lead-in period, patients received an oral dose of axitinib 7 mg twice daily (b.i.d.) (cohort 1) or 10 mg b.i.d. (cohort 2) for 7 days, followed by a 7-day interruption of axitinib treatment (week-on/week-off schedule). Cohort 1 initially enrolled three patients, and cohort 2 was opened if none of the three patients in cohort 1 experienced dose-limiting toxicities from the lead-in axitinib dose. Dose-limiting toxicities were defined as grade 4 neutropenia or thrombocytopenia for ⩾8 days, or grade 4 febrile neutropenia; proteinuria ⩾2 g per 24 h; uncontrolled grade⩾3 non-haematologic toxicity for ⩾14 days; or inability to resume axitinib, FOLFOX or FOLFIRI within 14 days after stopping due to treatment-related toxicity. If one or more of the three patients in cohort 1 experienced dose-limiting toxicities, three or more additional patients would be enrolled to assess the safety of the axitinib interrupted-dosing schedule. Patients in cohort 1 who tolerated the 7 mg b.i.d. lead-in dose of axitinib could have their dose titrated to 10 mg b.i.d. in a week-on/week-off schedule.

Following the lead-in period, axitinib and chemotherapy (FOLFIRI or FOLFOX) were administered in 2-week cycles. On day 1 of each cycle, patients received irinotecan 180 mg m^−2^ intravenous infusion over 90 min (or oxaliplatin 85 mg m^−2^ over 120 min) concurrently with leucovorin 400 mg m^−2^ over 2 h via separate infusion lines, followed by 5-FU 400 mg m^−2^ bolus, then 5-FU 2400 mg m^−2^ infusion over 46--48 h. The choice of chemotherapy was at the discretion of the investigator according to the standard of care and individual patient tolerability. Chemotherapy doses were specifically adjusted for neutropenia, thrombocytopenia, nausea, vomiting, diarrhoea, and peripheral sensory neuropathy and for grade ⩾3 toxicities possibly related to chemotherapy.

On day 3 of each cycle, axitinib b.i.d. dosing was started following completion of the 5-FU infusion. Axitinib dosing was interrupted on day 10 of each cycle for 7 days. The axitinib dose was reduced by one dose level in patients who developed grade 3 non-haematologic adverse events or two readings of systolic BP \>150 mm Hg or diastolic BP \>100 mm Hg while receiving maximal antihypertensive therapy. The axitinib dose was interrupted in patients with grade 4 axitinib-related adverse events, two readings of systolic BP \>160 mm Hg or diastolic BP \>105 mm Hg, or ⩾2 g protein per 24 h, and resumed at one lower dose level when adverse events improved to grade ⩽2, BP decreased to \<150/100 mm Hg, or\<2 g protein per 24 h was present. Patients were treated until disease progression or intolerable toxicity.

Assessments
-----------

Patients were evaluated by physical examination at screening, day 1 of each cycle and at end of treatment. Tumours were radiologically assessed at screening and every 6 weeks following study initiation, according to RECIST ([@bib25]). Safety was monitored throughout the study period, and adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) ([@bib26]). BP was measured at each clinic visit and b.i.d. by patients.

^18^FLT-PET/CT imaging
----------------------

During the lead-in period, ^18^FLT-PET/CT scans were performed before day 1, on day 7 of continuous axitinib dosing and on days 10 and 14 (i.e., third and seventh day of axitinib dosing interruption). A CT scan was obtained at the beginning of each imaging session using a combined PET/CT scanner (General Electric Discovery STE and Discovery VCT; General Electric Healthcare, Waukesha, WI, USA). Continuous dynamic PET scanning in two-dimensional mode was then performed for ∼30 min immediately following administration of a 185--259 MBq (5--7 mCi) bolus of ^18^FLT (Siemens Molecular Imaging, Knoxville, TN, USA). After dynamic imaging, static whole-body scans in three-dimensional mode were obtained starting at 60 min using 5-min acquisitions per bed position. Images were reconstructed using ordered-subset expectation maximisation. Metastatic lesions were identified using static whole-body imaging data. A maximum standardised uptake value (SUV) was obtained from a region of interest drawn over the largest area of a lesion. For a lesion located within a high background organ (e.g., the liver), mean SUV in the region of interest was used. Kinetic analyses were performed using the dynamic image data, and Patlak influx constant (*K*~pat~) was calculated ([@bib21]). The reported SUV or *K*~pat~ values are the measurements from the most intense lesion identified on the patient\'s first FLT-PET scan.

Statistical analysis
--------------------

Descriptive statistics were used for efficacy and safety data. For the FLT-PET data, a reference arterial input time activity curve (TAC) was extracted from a dynamic PET study using independent component analysis ([@bib9]). This TAC is known to be contaminated by a metabolic fraction (mf), which was modelled as mf=C\*(1.0−exp(−0.029\*T) where C is a coefficient ranging from 0.4 to 0.8 and T is time in minutes ([@bib21]). To minimise the effects of metabolites in determining the net uptake rate of FLT calculated with Patlak graphical analysis, only an early time interval was used (3--14 min).

Results
=======

Patients and treatment
----------------------

A total of 21 patients were enrolled between cohort 1 (*n*=3) and cohort 2 (*n*=18) ([Table 1](#tbl1){ref-type="table"}). Median duration of axitinib therapy was 527 days (range 55--663) in cohort 1 and 191 days (range 6--586) in cohort 2. Duration of axitinib therapy in individual patients is shown in [Figure 1](#fig1){ref-type="fig"}. Median daily dose of axitinib was 13.8 mg (range 12.4--14.0) in cohort 1 and 18.2 mg (range 9.3--20.0) in cohort 2. Fourteen patients received FOLFIRI and six received FOLFOX. Of 16 patients who had received previous chemotherapy, 9 received the same chemotherapy regimen in this study that they received previously (FOLFIRI in all cases). One patient with mCRC in cohort 2 did not receive chemotherapy. Median number of cycles of chemotherapy was 38 (range 4--48) in cohort 1 and 16 (range 2--42) in cohort 2. Twenty patients discontinued the study due to insufficient clinical response (*n*=13), withdrawal of consent (*n*=2), death due to disease progression (*n*=1) and adverse events (peripheral neuropathy, bacterial sepsis, elevated aspartate aminotransferase, and superior vena cava syndrome; *n*=1 each).

Safety
------

There were no dose-limiting toxicities from the lead-in axitinib dose in the first six patients enrolled in the study, and the maximum tolerated dose of axitinib was determined to be 10 mg b.i.d., in a week-on/week-off schedule, in combination with either FOLFIRI or FOLFOX. The most common grade ⩾3 adverse events, occurring in seven patients during the dose-limiting toxicity observation period, were hypertension (*n*=3), fatigue (*n*=2), and polyuria, Escherichia urinary tract infection, ascites, abdominal pain, hyponatremia, nausea, decreased appetite, and hypovolemia (*n*=1 each). Following the dose-limiting toxicity observation period, two patients receiving axitinib 10 mg b.i.d. required dose reductions or interruptions due to grade 3 hypertension during their first seven days of treatment with axitinib plus chemotherapy. The most frequently reported all-causality adverse events were fatigue (81%), nausea (76%), diarrhoea (67%), neutropenia (52%), and hypertension (48%) ([Table 2](#tbl2){ref-type="table"}). The most common grade 3 adverse events were neutropenia (38%), hypertension (33%), and fatigue (29%) ([Table 2](#tbl2){ref-type="table"}). Four grade 4 adverse events (aspartate aminotransferase increased, myocardial infarction, pulmonary embolism, and superior vena cava syndrome; *n*=1 each) and one grade 5 adverse event (disease progression) were reported. The axitinib dose was reduced in 6 (29%) patients and interrupted in 11 (52%) patients due to treatment-related adverse events.

Efficacy
--------

Two (10%) patients with CRC demonstrated a partial response, and twelve (57%) patients had stable disease. Maximum percentage change in tumour size by patient is shown in the [Supplementary Figure](#sup1){ref-type="supplementary-material"}. In the 17 patients with CRC, median progression-free survival (PFS) was 9.0 months (95% CI: 2.6--10.4) ([Figure 2](#fig2){ref-type="fig"}). One patient who discontinued chemotherapy after cycle 1 due to neutropenia continued to experience clinical benefit with single-agent axitinib (week-on/week-off schedule) and remains on therapy as of the data cutoff date.

^18^FLT-PET/CT imaging
----------------------

Complete sets of ^18^FLT-PET/CT data were available for 18 patients with lung (*n*=6), liver (*n*=5), lymph node (*n*=3) and abdominal wall and pelvic (*n*=2 each) lesions ([Figure 3A and B](#fig3){ref-type="fig"}). In one patient, no measurable lesion could be identified on either the dynamic or multi-bed images. Following an initial 7 days of continuous axitinib dosing, tumour ^18^FLT uptake (SUV) decreased --49% (s.e.m. 7%) from baseline ([Figure 3C](#fig3){ref-type="fig"}) in patients with liver lesions. Subsequently, following 3 and 7 days of axitinib interruption, tumour ^18^FLT uptake recovered to --28% (s.e.m. 7%) and --17% (s.e.m. 10%) from baseline, respectively. Maximum *K*~pat~ decreased --37% (s.e.m. 10%) from baseline after 7 days continuous axitinib dosing, and recovered to −27% (s.e.m. 14%) and +0.5% (s.e.m. 13%) from baseline, respectively, following 3 and 7 days of axitinib interruption ([Figure 3D](#fig3){ref-type="fig"}). Changes in ^18^FLT uptake by a target lesion in a representative patient are shown in [Figure 4](#fig4){ref-type="fig"}.

Discussion
==========

Enhanced efficacy with VEGF-binding agents, such as bevacizumab ([@bib11]; [@bib20]) or aflibercept ([@bib28]), in combination with chemotherapy is supported by the 'vascular normalisation\' hypothesis, which postulates that these agents normalise abnormal tumour vasculature and improve delivery of other anticancer therapies ([@bib13]). This hypothesis has been substantiated in numerous preclinical and clinical studies ([@bib6]). In contrast, to date none of the antiangiogenic TKIs have demonstrated improved efficacy in combination with chemotherapies in randomised phase II or phase III trials in mCRC ([@bib8], [@bib7]; [@bib27]; [@bib23]; [@bib4]); results from an ongoing, randomised phase II trial (NCT01478594) evaluating the VEGFR TKI tivozanib plus FOLFOX *vs* bevacizumab plus FOLFOX are still awaited. This may be explained by the transient nature of vascular normalisation with TKIs, beyond which marked vascular pruning or regression may actually result in decreased delivery of chemotherapeutic agents to tumours ([@bib6]). In addition, antiangiogenic TKIs may render tumours relatively hypoxic due to diminished blood flow and stop DNA synthesis, antagonising the cytotoxic effects of chemotherapies ([@bib14]). Taken together, this suggests that an interrupted schedule of antiangiogenic TKIs with a short half-life may be helpful in reversing the untoward effect on tumour vasculature and may optimise the intratumoural delivery of chemotherapeutic agents and restore tumour sensitivity. Intermittent dosing schedules may permit the use of antiangiogenic TKIs with reduced systemic toxicity and equivalent therapeutic benefit. The short half-life of axitinib (2--5 h) ([@bib18]) provided an opportunity to explore the impact of intermittent dosing of an antiangiogenic TKI on tumour blood flow, fluorodeoxythymidine uptake and antitumour efficacy.

In this study, axitinib administered in a week-on/week-off schedule in combination with FOLFIRI or FOLFOX was found to be well tolerated and demonstrated efficacy in patients with mCRC or other gastrointestinal tumours -- 76% of whom had received previous chemotherapy. Common adverse events reported here were fatigue, nausea, diarrhoea, hypertension, and neutropenia, which were anticipated based on results from phase II studies of single-agent axitinib treatment of different tumours ([@bib17]; [@bib3]; [@bib16]; [@bib22]; [@bib5]), as well as a phase I study of axitinib plus chemotherapy in patients with mCRC ([@bib24]). Noting that the majority of patients had received at least one previous chemotherapy regimen, our data suggest that interruption of axitinib dosing before administration of chemotherapy may improve clinical outcomes compared with continuous dosing. Although there is a risk of tumour progression when axitinib dosing is interrupted due to angiogenesis rebound, this effect was not observed in the present study. Further analysis of the efficacy and toxicity profiles of axitinib administered in an intermittent versus continuous dosing schedule in combination with chemotherapy would require further testing in a randomised clinical trial.

Imaging technology was proposed as a tool to quantify changes in tumour vasculature during antiangiogenic therapy and help optimise the dose and schedule of these agents in combination with chemotherapy ([@bib13]). ^18^FLT-PET imaging has already been explored as a non-invasive method for diagnosis, tumour staging, and response to therapy ([@bib1]). The present study used ^18^FLT-PET imaging to evaluate tumour cell proliferation following axitinib exposure and subsequent dosing interruption to help establish optimal administration of axitinib when combined with chemotherapy. Our ^18^FLT-PET results, based on data from both static (SUV) and dynamic (*K*~pat~) scans, suggest that tumour cell proliferation decreases during the period of treatment with axitinib followed by a rebound in tumour metabolic activity during the withdrawal phase. Since cytotoxic agents preferentially target proliferating tumour cells, the continuous concurrent dosing of axitinib in combination with cytotoxic agents may inhibit the activity of the cytotoxic agents. This effect may partially account for the lack of improved outcomes with continuous administration of axitinib combined with chemotherapy in patients with mCRC ([@bib2]; [@bib12]).

This study results suggest that axitinib administered in a week-on/week-off schedule in combination with chemotherapy may be an effective and well-tolerated treatment for CRC. This dosing strategy warrants further investigation.
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![**Duration of axitinib treatment.**](bjc2013806f1){#fig1}

![**Median progression-free survival for patients with colorectal cancer (*n*=17).** Abbreviations: CI=confidence interval; mPFS=median progression-free survival.](bjc2013806f2){#fig2}

![**Patient level (A) *SUV*~max~ scores (*n*=18) and (B) maximum *K*~pat~ values (*n*=13; 5 patients were missing baseline or follow-up measurements); percentage change from baseline in (C) *SUV*~max~ scores (*n*=18) and (D) maximum *K*~pat~ values (*n*=12).** ^a^*SUV*~mean~ scores and average *K*~pat~ values shown for the five patients with liver lesions. Abbreviations: *K*~pat~=Patlak influx constant; SUV=standardised uptake value.](bjc2013806f3){#fig3}

![**Changes in ^18^FLT uptake during and after axitinib treatment in a 3.0 × 3.1 cm^2^ right ilio-sacral region mass in a sample patient.** Arrows denote site of target lesion at (**A**) baseline; (**B**) day 7 axitinib dosing; (**C**) day 10 (3 days after stopping axitinib dose); (**D**) day 14 (7 days after stopping axitinib); and (**E**) computed tomography slide of corresponding region of reference. Abbreviations: ^18^FLT= \[^18^F\] fluorothymidine; *K*~pat~=Patlak influx constant; *SUV*~max~=maximum uptake value.](bjc2013806f4){#fig4}

###### Patient baseline characteristics

                                                                    ***N*****=21**
  ----------------------------------------------------------------- ------------------
  Male/female, *n* (%)                                              14 (67) / 7 (33)
  Median age (range), years                                         55 (41--69)
  **Race, *n* (%)**                                                 
  White                                                             16 (76)
  Black                                                             2 (10)
  Asian                                                             2 (10)
  Hispanic                                                          1 (5)
  **Primary tumour, *n* (%)**                                       
  Colorectal                                                        17 (81)
  Gastric                                                           2 (10)
  Gallbladder                                                       1 (5)
  Oesophageal                                                       1 (5)
  **ECOG PS, *n* (%)**                                              
  0                                                                 7 (33)
  1                                                                 13 (62)
  Not reported                                                      1 (5)
  **Metastatic sites followed for ^18^FLT-PET analyses, *n* (%)**   
  Lung                                                              6 (29)
  Liver                                                             5 (24)
  Lymph node                                                        3 (14)
  Abdominal wall                                                    2 (10)
  Pelvis                                                            2 (10)
  **Previous therapy, *n* (%)**                                     
  Surgery                                                           21 (100)
  Chemotherapy                                                      16 (76)
   1 prior regimen                                                  1 (5)
   2 prior regimens                                                 4 (19)
   3 prior regimens                                                 4 (19)
   \>3 prior regimens                                               7 (33)
  Radiation                                                         9 (43)

Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; ^18^FLT-PET=fluorine-18 3′-deoxy-3′-fluorothymidine positron emission tomography.

###### Treatment-emergent adverse events (all-causality)

  **Adverse event**[a](#t2-fn1){ref-type="fn"}   **Total** ***n*** **(%)**   **Grade 1** ***n*** **(%)**   **Grade 2** ***n*** **(%)**   **Grade 3** ***n*** **(%)**
  ---------------------------------------------- --------------------------- ----------------------------- ----------------------------- -----------------------------
  Fatigue                                        17 (81)                     2 (10)                        9 (43)                        6 (29)
  Nausea                                         16 (76)                     11 (52)                       4 (19)                        1 (5)
  Diarrhoea                                      14 (67)                     6 (29)                        7 (33)                        1 (5)
  Neutropenia                                    11 (52)                     1 (5)                         2 (10)                        8 (38)
  Hypertension                                   10 (48)                     2 (10)                        1 (5)                         7 (33)
  Vomiting                                       9 (43)                      3 (14)                        5 (24)                        1 (5)
  Dyspnoea                                       8 (38)                      3 (14)                        3 (14)                        2 (10)
  Back pain                                      7 (33)                      2 (10)                        3 (14)                        2 (10)
  Constipation                                   7 (33)                      4 (19)                        2 (10)                        1 (5)
  Hypotension                                    7 (33)                      3 (14)                        3 (14)                        1 (5)
  Mucosal inflammation                           7 (33)                      5 (24)                        2 (10)                        0
  Thrombocytopenia                               6 (29)                      4 (19)                        0                             2 (10)
  Headache                                       6 (29)                      4 (19)                        1 (5)                         1 (5)
  Anaemia                                        6 (29)                      4 (19)                        2 (10)                        0
  Decreased appetite                             6 (29)                      3 (14)                        2 (10)                        1 (5)
  Pyrexia                                        6 (29)                      3 (14)                        3 (14)                        0
  Abdominal pain                                 5 (24)                      3 (14)                        1 (5)                         1 (5)
  Dizziness                                      5 (24)                      2 (10)                        3 (14)                        0
  Hypokalaemia                                   5 (24)                      1 (5)                         1 (5)                         3 (14)
  Hypothyroidism                                 5 (24)                      3 (14)                        2 (10)                        0
  Peripheral neuropathy                          5 (24)                      4 (19)                        0                             1 (5)

Reported in \>20% of patients.
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